The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label, single-arm study to evaluate the efficacy of pembrolizumab for leukoplakia.
 
Maria Velez Velez
Honoraria - RoundTable Oncology
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Oncohost
Research Funding - Pfizer
 
Thu Ly
No Relationships to Disclose
 
Wanxing Chai-Ho
Consulting or Advisory Role - Ascentage Pharma; Blueprint Medicines; Novartis; Replimune
Research Funding - Agios; Akeso Biopharma; Ascentage Pharma; Asher Biotherapeutics; BMSi; Chimerix; Equillium; Gilead/Forty Seven; Merck; Novartis; Replimune; Shattuck Labs; Syndax; Syros Pharmaceuticals
 
Mark Swanson
No Relationships to Disclose
 
Meetal Dharia
No Relationships to Disclose
 
Eliot Abemayor
No Relationships to Disclose
 
Marilene Wang
No Relationships to Disclose
 
Robert Chin
No Relationships to Disclose
 
Allen Ho
No Relationships to Disclose
 
Diana Messadi
No Relationships to Disclose
 
Joel Epstein
No Relationships to Disclose
 
James Miranda
No Relationships to Disclose
 
Arturo Villanueva
No Relationships to Disclose
 
Nabilah Abdelaal
No Relationships to Disclose
 
Deborah Wong
Honoraria - Bicara Therapeutics
Consulting or Advisory Role - Bicara Therapeutics; Coherus Biosciences; Fennec Pharma; Merck; Merus; RAPT Therapeutics
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bicara Therapeutics (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Lilly; Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Sensei Biotherapeutics (Inst); Tempus (Inst); TopAlliance BioSciences Inc (Inst)
Travel, Accommodations, Expenses - Bicara Therapeutics; Merus; Regeneron